HHS Announces Department-Wide Clinical Trial Initiative - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

HHS Announces Department-Wide Clinical Trial Initiative

Agency-wide effort targets US clinical trial timelines, enrollment, and regulatory barriers.

  • By

  • mdspire news news staff

  • June 23, 2026

  • 7 min

Share

Objective:

To strengthen the US position in clinical research and accelerate the development of new treatments, as announced by the US Department of Health and Human Services.

Approach:
    Key Findings:
    • China's share of global Phase 1 trials surpassed that of the US for the first time in 2021.
    • The average time for a US sponsor's IND submission is approximately 380 days.
    • Fewer than 5% of cancer patients receive treatment through clinical trials despite high willingness to participate.
    Interpretation:

    The initiative aims to address delays in clinical trial processes and enhance the US's competitive edge in clinical research.

    Limitations:
    • The roadmap does not provide specific timelines for implementation of proposed changes.
    • Potential challenges in aligning multiple HHS agencies and stakeholders.
    Conclusion:

    The initiative represents a comprehensive effort to modernize and expedite clinical trial processes in the US.

    Sources:

Original Source(s)

HHS Announces Department-Wide Clinical Trial Initiative

  • by mdspire news news staff

  • June 23, 2026

Related Content

FDA Monthly Preview: Key July Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.

First HIV-Positive-to-HIV-Positive Lung Transplant Reported

The procedure was performed under a HOPE Act research protocol at an NYU Langone Health center the institution said is among the limited number of US transplant centers equipped and approved to perform HOPE lung transplants.

Lactate Biomarker May Predict Outcomes in Cardiogenic Shock

A review of cardiogenic shock studies suggests serial lactate measurements provide more prognostic information than isolated values and may better reflect treatment response.